Capricor Therapeutics, INC Schedule 13G passive stakes

State Street Corporation has reported beneficial ownership of 5.9% of Capricor Therapeutics Inc.'s common stock as of June 30, 2026.

RA Capital Management and its affiliates have reported beneficial ownership of 3,014,183 shares, representing 5.2% of Capricor Therapeutics' outstanding common stock.

Suvretta Capital Management and its affiliates have reported a passive beneficial ownership of 6.6% in Capricor Therapeutics, Inc. common stock.

Tang Capital Management and affiliated entities have reported a 6.6% beneficial ownership stake in Capricor Therapeutics, Inc. as of January 16, 2026.

The Vanguard Group has filed an amendment to its Schedule 13G, disclosing a 4.82% beneficial ownership in Capricor Therapeutics Inc. common stock.

The Vanguard Group has reported a beneficial ownership of 5.04% in Capricor Therapeutics Inc., holding over 2.3 million shares of common stock.

The Vanguard Group has filed an amended Schedule 13G, disclosing its passive beneficial ownership of 4.95% of Capricor Therapeutics Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.5% beneficial ownership stake in Capricor Therapeutics Inc. as of December 31, 2024.

The Vanguard Group has filed a Schedule 13G, disclosing a passive 5% ownership stake in Capricor Therapeutics Inc. as of December 31, 2024.